Dyne Therapeutics announced the appointment of John Cox as president, CEO and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition. Most recently, Cox served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Announces CEO Transition
- Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
- Dyne Therapeutics price target raised to $31 from $20 at Chardan
- Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
- Dyne Therapeutics price target raised to $29 from $27 at Piper Sandler